The Hamilton General Hospital (HGH) is a major teaching hospital in Downtown Hamilton, Ontario, Canada, located at the intersection of Barton Street East and Victoria Avenue North. It is operated by Hamilton Health Sciences and is formally affiliated with the Michael G. DeGroote School of Medicine at McMaster University.HGH has a high acute and emergency care burden, as 53.7% of patients are admitted through the emergency department (2020-2021). In 2020-2021, the average length of stay was 7.6 days and number of acute admissions was 45,165. HGH is one of the largest cardiac surgical centres in Canada, performing over 1,600 open heart surgeries annually. The hospital generated C$182,000,000 of research income in 2013, second to the University Health Network amongst research hospitals in Canada, and representing 14.8% of its income.HGH is also one of the largest trauma, neurosurgery, and stroke centres in Canada. They perform over 1000 neurosurgical procedures annually. It is an accredited centre of Distinction in Stroke Services for demonstrating clinical excellence in Acute Stroke Services and Inpatient Stroke Rehabilitation Services.
BACKGROUND:Apixaban and rivaroxaban are the oral anticoagulants most frequently used to treat acute venous thromboembolism. However, uncertainty remains about the difference in bleeding risk between the two medications. METHODS:In an international trial with a prospective, randomized, open-label, blinded end-point design, we assigned, in a 1:1 ratio, eligible patients with acute symptomatic pulmonary embolism or proximal deep-vein thrombosis to receive apixaban or rivaroxaban for 3 months. Apixaban was given at a dose of 10 mg twice daily for 7 days followed by 5 mg twice daily, and rivaroxaban was given at a dose of 15 mg twice daily for 21 days followed by 20 mg daily. The primary outcome was clinically relevant bleeding, a composite of major bleeding or clinically relevant nonmajor bleeding, as defined according to the International Society on Thrombosis and Haemostasis, during the 3-month trial period. Secondary outcomes included death from any cause. RESULTS:A total of 2760 patients underwent randomization: 1370 to the apixaban group and 1390 to the rivaroxaban group. A primary-outcome event occurred in 44 of 1345 patients (3.3%) in the apixaban group and 96 of 1355 patients (7.1%) in the rivaroxaban group (relative risk, 0.46; 95% confidence interval [CI], 0.33 to 0.65; P<0.001). Death from any cause occurred in 1 patient (0.1%) in the apixaban group and in 4 patients (0.3%) in the rivaroxaban group (relative risk, 0.25; 95% CI, 0.03 to 2.26). Serious adverse events unrelated to bleeding or venous thrombosis occurred in 36 patients (2.7%) in the apixaban group and in 30 patients (2.2%) in the rivaroxaban group. CONCLUSIONS:Among patients with acute venous thromboembolism, the risk of clinically relevant bleeding was significantly lower with apixaban than with rivaroxaban during the 3-month treatment period. (Funded by the Canadian Institutes of Health Research and others; COBRRA ClinicalTrials.gov number, NCT03266783.).
Abstract Background Cavotricuspid isthmus (CTI) ablation is the standard treatment for typical atrial flutter (AFL), yet marked anatomical variability can influence procedural workload and outcomes. Intracardiac echocardiography (ICE) allows direct visualisation of isthmus morphology and may guide ablation strategy. Purpose To assess whether an ICE-derived CTI morphology score predicts ablation workload and clinical outcomes during fluoroless CTI ablation for typical AFL. Methods In a retrospective cohort of 200 consecutive patients undergoing CTI ablation guided by three-dimensional electroanatomical mapping and ICE, CTI anatomy was graded with a 0–6 morphology score combining five features: CTI length > 35 mm (1), pouch (1), ridge (1), thick or prominent Eustachian valve (2), and concave shape (1). Primary endpoints were radiofrequency (RF) ablation time and number of applications. Secondary endpoints were acute bidirectional CTI block and late AFL recurrence (> 3 months). Results Grades were mild 0–1 (58.5%), moderate 2–3 (35.5%), and severe 4–6 (6.0%). Acute block was achieved in 99.5%. Each 1-point higher CTI score predicted greater workload: approximately +50 s RF time and +4 additional applications per point (both p < 0.001). The score was not associated with acute success but showed a trend toward higher late AFL recurrence (7.0% overall). Complications were rare (1% groin haematoma). Conclusion(s) An ICE-derived CTI morphology score provides a reproducible intra-procedural measure of anatomical complexity, predicting ablation workload without compromising safety or acute success. Although its discrimination for late recurrence is modest, it offers practical value for procedural planning and operator guidance in fluoroless AFL ablation.C.I